Tags

Type your tag names separated by a space and hit enter

Coronavirus Disease 2019 (COVID-19) Vaccines and Pregnancy: What Obstetricians Need to Know.
Obstet Gynecol. 2021 Mar 01; 137(3):408-414.OG

Abstract

Coronavirus disease 2019 (COVID-19) vaccines have begun to be distributed across the United States and to be offered initially to priority groups including health care personnel and persons living in long-term care facilities. Guidance regarding whether pregnant persons should receive a COVID-19 vaccine is needed. Because pregnant persons were excluded from the initial phase 3 clinical trials of COVID-19 vaccines, limited data are available on their efficacy and safety during pregnancy. After developmental and reproductive toxicology studies are completed, some companies are expected to conduct clinical trials in pregnant persons. Until then, pregnant persons and their obstetricians will need to use available data to weigh the benefits and risks of COVID-19 vaccines. Issues to be considered when counseling pregnant persons include data from animal studies and inadvertently exposed pregnancies during vaccine clinical trials when available, potential risks to pregnancy of vaccine reactogenicity, timing of vaccination during pregnancy, evidence for safety of other vaccines during pregnancy, risk of COVID-19 complications due to pregnancy and the pregnant person's underlying conditions, and risk of exposure to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and potential for risk mitigation. The Centers for Disease Control and Prevention, the American College of Obstetricians and Gynecologists, and the Society for Maternal-Fetal Medicine have each issued guidance supportive of offering COVID-19 vaccine to pregnant persons. As additional information from clinical trials and from data collected on vaccinated pregnant persons becomes available, it will be critical for obstetricians to keep up to date with this information.

Authors+Show Affiliations

Departments of Pediatrics, Obstetrics and Gynecology, and Epidemiology, University of Florida College of Medicine and College of Public Health and Health Professions, Gainesville, Florida; and the Division of Infectious Diseases and the Department of Gynecology and Obstetrics, Emory University School of Medicine, Atlanta, the Grady Healthcare System, Infectious Diseases Program, Atlanta, and the Hope Clinic of the Emory Vaccine Center, Decatur, Georgia.No affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

33370015

Citation

Rasmussen, Sonja A., et al. "Coronavirus Disease 2019 (COVID-19) Vaccines and Pregnancy: what Obstetricians Need to Know." Obstetrics and Gynecology, vol. 137, no. 3, 2021, pp. 408-414.
Rasmussen SA, Kelley CF, Horton JP, et al. Coronavirus Disease 2019 (COVID-19) Vaccines and Pregnancy: What Obstetricians Need to Know. Obstet Gynecol. 2021;137(3):408-414.
Rasmussen, S. A., Kelley, C. F., Horton, J. P., & Jamieson, D. J. (2021). Coronavirus Disease 2019 (COVID-19) Vaccines and Pregnancy: What Obstetricians Need to Know. Obstetrics and Gynecology, 137(3), 408-414. https://doi.org/10.1097/AOG.0000000000004290
Rasmussen SA, et al. Coronavirus Disease 2019 (COVID-19) Vaccines and Pregnancy: what Obstetricians Need to Know. Obstet Gynecol. 2021 Mar 1;137(3):408-414. PubMed PMID: 33370015.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Coronavirus Disease 2019 (COVID-19) Vaccines and Pregnancy: What Obstetricians Need to Know. AU - Rasmussen,Sonja A, AU - Kelley,Colleen F, AU - Horton,John P, AU - Jamieson,Denise J, PY - 2020/12/13/received PY - 2020/12/16/accepted PY - 2020/12/29/pubmed PY - 2021/2/24/medline PY - 2020/12/28/entrez SP - 408 EP - 414 JF - Obstetrics and gynecology JO - Obstet Gynecol VL - 137 IS - 3 N2 - Coronavirus disease 2019 (COVID-19) vaccines have begun to be distributed across the United States and to be offered initially to priority groups including health care personnel and persons living in long-term care facilities. Guidance regarding whether pregnant persons should receive a COVID-19 vaccine is needed. Because pregnant persons were excluded from the initial phase 3 clinical trials of COVID-19 vaccines, limited data are available on their efficacy and safety during pregnancy. After developmental and reproductive toxicology studies are completed, some companies are expected to conduct clinical trials in pregnant persons. Until then, pregnant persons and their obstetricians will need to use available data to weigh the benefits and risks of COVID-19 vaccines. Issues to be considered when counseling pregnant persons include data from animal studies and inadvertently exposed pregnancies during vaccine clinical trials when available, potential risks to pregnancy of vaccine reactogenicity, timing of vaccination during pregnancy, evidence for safety of other vaccines during pregnancy, risk of COVID-19 complications due to pregnancy and the pregnant person's underlying conditions, and risk of exposure to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and potential for risk mitigation. The Centers for Disease Control and Prevention, the American College of Obstetricians and Gynecologists, and the Society for Maternal-Fetal Medicine have each issued guidance supportive of offering COVID-19 vaccine to pregnant persons. As additional information from clinical trials and from data collected on vaccinated pregnant persons becomes available, it will be critical for obstetricians to keep up to date with this information. SN - 1873-233X UR - https://www.unboundmedicine.com/medline/citation/33370015/Coronavirus_Disease_2019__COVID_19__Vaccines_and_Pregnancy:_What_Obstetricians_Need_to_Know_ DB - PRIME DP - Unbound Medicine ER -